2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium

BACKGROUND: Staphylococcus aureus (SA) pneumonia imposes significant morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, AT-neutralizing antibodies (AT NAbs), and safety of suvratoxumab (suvra) in MV ICU subj...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Open Forum Infect Dis
Huvudupphovsmän: Francois, Bruno, Sánchez Garcia, Miguel, Eggimann, Philippe, Dequin, Pierre-Francois, Laterre, Pierre-François, Huberlant, Vincent, Viña Soria, Lucia, Boulain, Thierry, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Catalina Hernandez Padilla, Ana, Coenjaerts, Frank, Ali, Omar, Shoemaker, Kathryn, Ruzin, Alexey, Pierre, Vadryn, Wu, Yuling, Colbert, Susan, McCarthy, Michael, Dubovsky, Filip, S. Jafri, Hasan
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2019
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809370/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.144
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk